Introduction
Transforming growth factor alpha (TGF-␣) is a polypeptide growth factor that binds exclusively to the epidermal growth factor receptor (EGFR). 1, 2 It is synthesized as a larger, membrane-bound glycoprotein (proTGF-␣), which is cleaved to release a soluble 50 amino acid polypeptide (TGF-␣). TGF-␣ plays an important role in regulating growth and development of a variety of cells including skin, 3, 4 mammary epithelium, 5 GI tract mucosa, 6 brain, 7 gynecologic and reproductive organs, 8 kidney, and bladder. 9 Overexpression of TGF-␣ alone, or in combination with EGFR, leads to colony formation in soft agar and tumor formation in nude mice, thus linking TGF-␣ to transformation. 10 TGF-␣ transgenic mice display evidence of epithelial hyperplasia, pancreatic metaplasia and carcinoma of the breast. 11 Co-expression of TGF-␣ and EGFR has also been implicated in the pathophysiology of human cancer. Overexpression of TGF-␣ alone, or in combination with EGFR, has been reported in primary malignancies and cell lines established from a wide variety of tumors, including glioblastoma, 12, 13 cancers of the breast, 14, 15 esophagus, remained localized to the nucleus for up to 3 days. Direct inoculation of the TGF-␣ antisense (but not the corresponding sense) construct into established HNSCC tumors resulted in inhibition of tumor growth. Sustained antitumor effects were observed for up to 1 year after the treatments were discontinued. Down-modulation of TGF-␣ was accompanied by increased apoptosis in vivo. These experiments indicate that interference with the TGF-␣/EGFR autocrine signaling pathway may be an effective therapeutic strategy for cancers which overexpress this ligand/receptor pair. Gene Therapy (2000) 7, 1906-1914. by the same tumor cell provides indirect evidence of an autocrine regulatory pathway. Reports suggest that the maintenance of an autocrine loop in HNSCC is dependent on both elevated levels of EGFR and the presence of TGF-␣. 30, 31 TGF-␣ overexpression has been implicated as a poor prognostic factor in cancers of the kidney 32 and esophagus. 16 The biologic importance of this growth factor in head and neck cancer progression is supported by our findings demonstrating that survival of HNSCC patients correlates significantly with TGF-␣ protein expression levels in the primary tumor, independent of other clinical and pathological parameters including the presence of regional metastases (N-stage). 33 The observation that elevated levels of TGF-␣ are associated with the loss of growth control in many cancers has led to the development of strategies aimed at down-modulating this growth factor in an attempt to decrease tumor cell proliferation.
Results
We previously reported that TGF-␣ antisense oligonucleotides inhibited the growth of HNSCC but not normal mucosal cells in vitro, suggesting that the growth stimulating effects of TGF-␣ are specific for transformed squamous epithelial cells. 34 To determine the consequences of targeting TGF-␣ in vivo, we cloned a TGF-␣ antisense sequence designed against the translation initiation site of the human TGF-␣ gene into an expression vector based on the U6 small nuclear RNA (snRNA) promoter. 
TGF-␣ antisense gene therapy inhibits tumor growth
To determine whether or not the injected gene could be detected in the tumors, DNA was harvested from the treated xenografts followed by PCR using specific primers designed to detect the recombinant TGF-␣ sense or antisense gene. The recombinant DNA was detected in all tumors in contrast to tumors treated with liposomes alone (Figure 4) . To examine the consequences of the transfected TGF-␣ antisense gene on tumor growth in vivo, established HNSCC xenografts were repeatedly inoculated with 50 g TGF-␣ antisense DNA plus 50 nmol DC-chol liposomes. Previous studies from our laboratory have demonstrated the necessity of a carrier mol- ecule such as DC-chol to achieve an antitumor effect. 35 Dose-response experiments using a similar approach to target EGFR showed equal antitumor efficacy using 25 g or 50 g of DNA per injection with less antitumor effects seen at lower doses (2.5 g, 0.25 g, 0.025 g).
35
In contrast to tumors treated with TGF-␣ sense DNA plus liposomes or tumors treated with liposomes alone, HNSCC xenografts inoculated with TGF-␣ antisense DNA plus liposomes were growth inhibited ( Figure 5 ). To determine the persistence of the antitumor effects, a subset of mice treated with the TGF-␣ antisense construct plus liposomes were maintained and followed for up to 1 year after the treatments were discontinued. In these mice, the tumors completely disappeared after therapy was discontinued and did not re-grow (data not shown). Although the immune system may play a role in tumor clearance, use of an athymic nude mouse model in these studies, limits the ability to implicate immune mechanisms.
Modulation of TGF-␣ protein expression by TGF-␣ antisense gene therapy
To determine whether the antitumor effects observed with TGF-␣ antisense gene therapy were associated with decreased TGF-␣ protein expression, tumors were harvested following treatment and immunohistochemistry was performed using a TGF-␣ monoclonal antibody. Treatment with TGF-␣ antisense gene therapy resulted in decreased TGF-␣ staining intensity in the tumor cells suggesting that the antitumor effects observed are a direct result of abrogation of TGF-␣ gene expression ( Figure 6 ).
Figure 5 In vivo growth inhibition of HNSCC xenografts. The growth inhibitory effects of the TGF-␣ antisense construct in a representative experiment is demonstrated. Groups of mice received intratumoral treatments (three times a week) with TGF-␣ antisense DNA plus liposomes (᭺), TGF-␣ sense DNA plus liposomens (ȣ), or liposomes alone () 14-21 days following tumor implantation. All cases received nine treatments. Each point represents the mean value for eight to 10 tumors from an individual experiment that was replicated three times. Fractional tumor volume (tumor volume as a proportion of pretreatment volume) is plotted and the standard error of tumor volumes for all points was less than 10% of the mean. Statistical analysis was performed comparing fractional tumor volumes in the TGF-␣ antisense-treated group with the sensetreated group at each time-point and significant values (*) were obtained at nearly all time-points (two-sided; P Ͻ 0.05).
Increased apoptosis and decreased proliferation are associated with TGF-␣ antisense gene therapy To investigate the mechanism of the antitumor effect induced by treatment with the TGF-␣ antisense DNA plus liposomes, we examined hematoxylin and eosin staining of the tumors and were unable to detect a difference in necrosis between treatment groups (data not shown). To determine whether the observed growth inhibition was associated with an increase in the rate of apoptosis, tumors were stained for DNA fragmentation (ApopTag). Results demonstrated a two-fold elevation in the number of apoptotic tumor cells in xenografts treated with the TGF-␣ antisense construct plus liposomes compared with tumors treated with the corresponding sense construct (P Ͻ 0.001) or liposomes alone (P = 0.002); proteins, including Bcl-2 and Bax, were not affected by TGF-␣ antisense gene therapy.
Discussion
Overexpression of TGF-␣ is prevalent in a variety of malignant neoplasms as well as established tumor cell lines. Previous studies in our laboratory demonstrated increased expression of TGF-␣ in HNSCCs compared with normal mucosa, primarily as a result of activated gene transcription. 36 Patients with HNSCC are at high risk of developing additional cancers of the aerodigestive tract. This predisposition to tumor formation is thought to be due to toxin (tobacco and alcohol) exposure of the entire mucosa (field cancerization) leading to cumulative genetic alterations. Our earlier findings of elevated TGF-␣ in this mucosa from HNSCC patients as well as in premalignant, dysplastic lesions, suggests that up-regulation of TGF-␣ represents an early event in HNSCC carcinogenesis. 28, 29, 37 The observation that TGF-␣ gene expression may be regulated by chemopreventive agents, such as retinoic acid in HNSCC cells, provides further evidence that TGF-␣ may serve a target for prevention strategies in aerodigestive tract cancers. 36 The critical biologic role of TGF-␣ in HNSCC is supported by our finding that TGF-␣ expression levels in the primary HNSCC tumor correlates with decreased survival, independent of other clinical and pathologic parameters, including lymph node metastases. 33 Previous therapeutic approaches designed to abrogate TGF-␣ in vitro have included the use of neutralizing antibodies or antisense oligonucleotides. TGF-␣ monoclonal antibody treatment has been shown to inhibit the growth of lung cancer cell lines, 38 chemically induced mouse intestine cancer cells, 39 and human colon cancer cell lines in vitro. 40 DNA synthesis is reportedly decreased in both HNSCC cells 41 and ovarian cancer cells 26 following TGF-␣ antibody treatment. We and others have reported inhibition of cancer cell line growth following treatment with TGF-␣ antisense oligonucleotides or an expression vector in vitro. 34, 42 In our earlier study, TGF-␣ antisense oligonucleotides down-modulated TGF-␣ protein expression in both HNSCC and normal mucosal epithelial cells. However, the normal cells were not growth inhibited by TGF-␣ antisense oligonucleotide treatment suggesting that the proliferative effects of TGF-␣ are specific for transformed cells. 34 Several groups have reported the consequences of TGF-␣ targeting in vivo. Implanted LE2 mouse cells transfected with a TGF-␣ antisense expression vector showed slower growth compared with that of parental cells transfected with control vector alone. 42 Using a prostate cancer xenograft model, Rubenstein et al 43 demonstrated abrogation of tumor growth following intratumoral injection of large doses (Ͼ400 g) of TGF-␣ antisense oligonucleotides. While the adverse effects of synthetic antisense oligonucleotides appear to be minimal, there is little evidence that they are efficacious against solid tumors.
44,45 Administration of a TGF-␣ antisense oligonucleotide directly into tumors implanted subcutaneously into nude mice resulted in rapid diffusion of the radiolabeled oligonucleotide from the tumor to the digestive and urinary tracts. 46 To determine the role of TGF-␣ in HNSCC in vivo, we treated HNSCC-bearing mice with intratumoral administration of a TGF-␣ antisense gene therapy construct in combination with DC-chol liposomes. In these studies, we elected to use an antisense expression construct designed to achieve high levels of antisense RNA expression intracellularly. A corresponding sense construct was generated and utilized as a DNA control, although a mismatch or scramble sequence may have provided stronger evidence of a specific antisense mechanism of action. Although the ideal cancer gene therapy would be administered systemically with preferential localization to the tumor, head and neck cancers are amenable to intralesional therapy due to the accessibility of the tumors and the relatively low incidence of distant metastases. To deliver the antisense gene to the tumor cells, we chose a nonvirus-mediated gene transfer strategy. This approach offers several theoretical advantages over virally mediated gene delivery including low toxicity, lack of immunogenicity and inflammatory reactions, and the relative ease of obtaining large quantities of vector. DC-chol liposomes increase DNA uptake into cells compared with naked DNA alone. 47 Several clinical trials have used DC-chol liposomes with negligible toxicity reported, including the delivery of the allogeneic MHC gene into melanoma tumor sites and CFTR gene transfer into the lungs of patients with cystic fibrosis. 48, 49 The chief disadvantage of liposome-mediated gene transfer is the relatively low transfection efficiency compared with that of viral vectors.
Several promoters are available for in vivo gene transfer strategies. We elected to use the U6 snRNA promoter, which was originally engineered to express large amounts of short RNA sequences. 50 U6 snRNA is one of the small nuclear RNAs which participates in RNA splicing and is constitutively expressed (approximately half a million copies per cell) in almost all cells. In direct comparison studies, the amount of U6 product is significantly higher than that of genes expressed under the control of the CMV promoter. 47 Localization and trafficing of vector expressing antisense RNA and/or antisense oligodeoxynucleotides depends on their chemical modification as well as the vector from which it is expressed. Our finding of labeled DNA in the nucleus at 12, 24, 48 and 72 h after transduction suggests that liposome-mediated transfer of the TGF-␣ antisense construct facilitates delivery of sequence into the cell which is sustained for at least 3 days.
In this study, antitumor efficacy of TGF-␣ antisense gene therapy was accompanied by increased apoptosis. Growth factors, such as TGF-␣, often stimulate proliferation of cells expressing (or overexpressing) receptors for that growth factor. The relationship between TGF-␣ function and apoptosis is less well understood. Studies examining nontransformed cells in vitro include the observation that rat enterochromaffin-like cells demonstrate decreased apoptosis when exposed to TGF-␣, 51 and exogenous TGF-␣ reduces the incidence of apoptosis in developing mouse blastocysts. 52 In cancer cells, several reports also suggest that TGF-␣ may serve as an antiapoptotic factor. TGF-␣ inhibits c-myc-induced apoptosis in a mouse mammary tumor model 53 whereas apoptosis is induced in liver cancer cells expressing TGF-␣ following treatment with TGF-␣ neutralizing antibodies. 54, 55 Our finding of increased apoptosis in HNSCC cells following antisense targeting of TGF-␣ in vivo, accompanied by decreased Bcl-x L expression, suggests that autocrine production of TGF-␣ by HNSCC cells may abrogate apoptosis via selective modulation of apoptotic regulatory proteins.
TGF-␣ stimulates and exerts its biologic effects exclusively through the EGFR. We have previously demonstrated that the autocrine production of TGF-␣ by HNSCC cells which express EGF receptors results in a growth pathway that has prognostic implications. In a survival analysis, levels of TGF-␣ in the tumor were highly correlated with EGFR expression levels. 33 Tar-geting either ligand or receptor alone, in vitro, inhibits the growth of HNSCC cells. 34, 56 Previous reports combining TGF-␣ antisense oligonucleotides with an EGFR-specific tyrosine kinase inhibitor or a protein kinase A inhibitor in vitro, suggested that increased growth inhibition could be achieved by targeting the ligand simultaneously with a downstream signaling peptide. 41, 57 TGF-␣ antisense oligonucleotides have also been used in conjunction with one of several chemotherapy agents where combined treatment demonstrated increased growth inhibition of colon cancer cells compared with TGF-␣ antisense oligonucleotide alone. 58 Treatments designed to abrogate TGF-␣ production represent a potential means of inhibiting tumor growth in cancers which overexpress this growth factor.
Materials and methods

Plasmid construct and cloning
We modified the original U6 expression plasmid (pGEMmU6; a kind gift from S Noonberg, University of California San Francisco Research Institute 50 ), as described previously. 35 Forty base pair long sense and antisense oligonucleotides corresponding to the ATG start site of the human TGF-␣ gene (−20 to +20) 59 were synthesized and cloned into the Xhol and Nsil sites of the modified plasmid, p⌬HU6. The sequences of the sense and antisense expression constructs were verified by sequence analysis (Figure 1 ).
Cells
The cell line, 1483, is a well-described HNSCC cell line derived from a tumor of the retromolar trigone region of the oropharynx 60 and was a generous gift of Dr R Lotan (The University of Texas MD Anderson Cancer Center, Houston, TX, USA). We previously reported that 1483 cells, like all HNSCC cell lines, produce TGF-␣ and are significantly growth inhibited in vitro following treatment with TGF-␣ antisense oligonucleotides. 34 The cells were maintained in vitro in Dulbecco's modified Eagle's medium (DMEM) (Fisher Scientific, Pittsburgh, PA, USA) supplemented with 10% fetal calf serum (FCS) and antibiotics (Life Technologies (GIBCO BRL), Gaithersburg, MD, USA).
In vivo tumor xenograft studies
We and others have previously reported that the 1483 cell line grows well as xenografts in nude mice. 35, 60 Cells in log phase were harvested by trypsinization, resuspended in DMEM supplemented with 10% FCS, centrifuged at 1000 r.p.m. for 10 min, and resuspended in culture media at a concentration of 1 × 10 7 cells/ml before subcutaneous implantation into mice. Female athymic nude mice nu/nu (4-6 weeks old; 20 ± 2 g (s.d.); Harlan Sprague Dawley, Indianapolis, IN, USA) were implanted with 1 × 10 6 cells into the right flank with a 26-gauge needle/1 ml tuberculin syringe. Approximately 14-21 days later when the tumor nodules were palpable (approximately 2 × 2 mm in diameter), mice were randomly assigned to the treatment groups. Mice were treated with liposomes alone, TGF-␣ antisense DNA plus liposomes or TGF-␣ sense DNA plus liposomes. There were 10 mice in each treatment group in an individual experiment. Experiments were repeated three times to ensure reproduciGene Therapy bility. Intratumoral injection of plasmid DNA (50 g) complexed with DC-chol liposomes (50 nmol) in a volume of 50 l (three times a week for 3 weeks or a total of nine injections) was performed. Tumors were measured using calipers before each injection and tumor volumes were calculated (tumor volume = length × width 2 /2; fractional tumor volume calculated as a proportion of the pretreatment tumor volume). Mice were killed when the tumors ulcerated or reached a maximum diameter of 2 cm. Animal care was in strict compliance with institutional guidelines established by the University of Pittsburgh, the Guide for the Care and Use of Laboratory Animals, and the Association for Assessment and Accreditation of Laboratory Animal Care International.
Polymerase chain reaction (PCR)
To detect the U6/TGF-␣ chimeric DNA in the tumor following intratumoral injection of the plasmid-liposome complex, nucleic acids were extracted from harvested xenografts using Ultraspec (Biotecx Laboratories, Houston, TX, USA). One microgram of the total RNA combined with plasmid DNA was digested with 10 g of RNase A (GIBCO BRL). The RNase was removed by phenol: chloroform: isoamyl alcohol (25:24:1) extraction. PCR was performed using primers designed to detect U6 DNA and the U6/TGF-␣ chimeric DNA under the conditions recommended by the manufacturer. For the TGF-␣ antisense gene, the forward primer was AAA CGC ACC ACG TGA CGG and the reverse primer was TGC ATT GCT GCC CGC CCG. For the TGF-␣ sense gene, the forward primer was AAA CGC ACC ACG TGA CGG and the reverse primer was CTG TCC AGC CGA GGG GAC. The PCR products were run on a 1% agarose gel.
Intracellular localization of transfected DNA
To determine the intracellular localization of the TGF-␣ antisense construct after delivery into HNSCC cells, we examined fluorecein-labeled DNA in transfected tumor cells using fluorescence microscopy. The DNA was labeled with Labet IT fluorecein nucleic acid labeling kit (Molecular Probes, Eugene, OR, USA). Five micrograms of DNA were mixed with 5 l of 10 × labeling buffer A and 5 l of reconstituted labeling reagent in a reaction performed at 37°C for 1 h followed by a purification with a G50 spin column. 1483 Cells were plated on 60-mm cell culture dished with a glass cover slip on the bottom at a density of 2 × 10 6 cell per well. These cells were transfected 24 h later with a DNA-liposome mixture of 7 glabeled DNA and 24 l LipofectAMINE reagent (GIBCO BRL) for each dish according to the manufacturer's instructions. Cells alone, cells treated with labeled DNA only, and cells treated with unlabeled DNA plus LipofectAMINE under the same transfection conditions were used as controls for substracting the false positive signals. Cells transfected with fluorescent DNA were counterstained with Hoechst nuclear strain (Molecular Probes) and imaged on a Zeiss 135 axivert scope (Zeiss, Thornwood, NY, USA) with an automated xyz stage. For each transfection time-point (5 h, 12 h, 24 h, 48 h, 72 h) five separate fields were imaged in the xy axis at 30 different z axis positions. Data stacks for each field were used to create 360°three-dimensional reconstructions to verify nuclear localization. Standard fluorescent filter sets (Chroma Tech, Brattleboro, VT, USA) for FITC and DAPI were used in these studies. Tissue samples were fixed in 2% parafomaldehyde in PBS for 1 h at 4°C, cryoprotected in 30% sucrose overnight and chock frozen in liquid nitrogen cooled isopentane. Sections (5 microns) were cut using a Microm (Walldorf, Germany) 505E cryostat mounted on glass slides and counterstained with DAPI (1 mg/100 ml) for 2 min. The slides were then coverslipped in glycerol and the sections examined using an Olympus (Melville, NY, USA) IX70 microscope with a 40 × planapochromat oil immersion objective and a double pass (green/blue) cube. Images were captured using an Optronics Firewire camera (Galeta, CA, USA) and stored. Subsequently, the coverslips were lifted from the slides by immersion in PBS and slides passed through a standard hematoxylin and eosin series and remounted in Permount. The exact areas imaged using fluorescence microscopy were then captured using brightfield illumination.
Immunohistochemistry
Tumor specimens (HNSCC xenografts) were fixed immediately following resection in 10% buffered neutral formalin and stained with hematoxylin and eosin for histopathologic analysis. Indirect immunohistochemical staining for TGF-␣ (Antibody 2; Oncogene Science, Uniondale, NY, USA) was performed on paraffin-embedded tissues using a murine monoclonal antibody from a commercially available assay as described by us previously. 29, 33 The labeled streptoavidin-biotin (LSAB) method was used to visualize antibody positivity (DAKO LSAB + kits; DAKO Corporation, Carpinteria, CA, USA). The primary antibody was a mouse antihuman IgG and the secondary antibody was a horse antimouse biotinylated IgG (Bio-Rad Laboratories, Hercules, CA, USA). Brown staining was considered positive. Positive and negative controls were as described previously. 33 Apoptosis determinations/DNA fragmentation The percentage of apoptotic cells in tumors treated with the TGF-␣ antisense (versus sense) gene therapy was determined by staining for DNA fragmentation with ApopTag (INTERGEN, Purchase, NY, USA). Tumors were harvested, sectioned, fixed in formalin and paraffinembedded, then incubated with proteinase K diluted in phosphate-buffered saline (PBS) for 20 min and washed four times in water. Slides were then incubated in 3% H 2 O 2 in PBS for 5 min and washed twice in PBS. Each section was incubated with a terminal transferase enzyme that catalyzes the addition of digoxigenin-labeled nucleotides to the 3Ј-OH ends of the fragmented DNA for 15 min at 37°C. Slides were then placed in stop buffer for 30 min at 37°C, followed by washing three times in PBS for 5 min. Negative controls were obtained by substituting dH 2 O for the terminal deoxynucleotidyl transferase mix. Slides were read and scored under 400 × magnifications for the number of positive cells per five high power fields using computerized image analysis as described previously 61 (SAMBA 4000 Image Analysis System; Image Products International; Chantilly, VA, USA).
Immunoblotting
Whole-cell extracts from tumors were mixed with 2 × sodium dodecyl sulfate (SDS) sample buffer (125 mmol/l Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 10% 2-mercaptoethanol) at 1:1 ratio and were heated for 5 min at 100°C. Proteins (50 g per lane) were separated by 12.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred on to a nitrocellulose membrane (MSI, Westboro, MA, USA). Prestained molecular weight markers (Gibco, Gaithersburg, MD, USA) were included in each gel. Membranes were blocked for 30 min in Trisbuffered saline (TBS: 10 mmol/l Tris-HCl, pH 7.5, and 150 mmol/l NaCl) with 0.5% Tween-20 (TBST) and 5% bovine serum albumin (BSA). After blocking, membranes were incubated for 60 min with Bcl-x L mouse anti-human monoclonal antibody or a Bax rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) in TBST and 1% BSA. After washing the membranes three times with TBST (5 min each), they were incubated with horseradish peroxidase-conjugated secondary antibody in TBST and 1% BSA for 30 min. Subsequently, membranes were washed three times with TBST and developed using the enhanced chemiluminescence (ECL) detection system (Amersham Life Sciences, Arlington Heights, IL, USA).
Statistical analysis
For in vivo experiments where tumor volumes of the same mice were measured over time, the statistical significance of differences between groups was examined by use of repeated measurement analysis of variance (twosided). Comparisons were restricted to mice treated in the same experiment. For apoptosis studies, the statistical significance of differences in apoptosis was assessed by use of Student's t test (two-sided) that ensured unequal variance.
